Immunocompromised/disordered, thrombocytopenia, multiple myeloma, post-transplant patients, and the New Crown vaccine are covered in previous sections, please see previous section descriptions and will not be repeated here. This article focuses on whether or not the New Crown vaccine can be given for blood disorders not previously described. The most common adverse reactions to the inactivated vaccine in the United States are pain at the injection site (up to 60%), fever (up to 50%), headache (up to 42%), fatigue (up to 28%), joint pain (up to 24%), muscle pain, and nausea. However, the FDA reported only three cases of severe allergic reactions. In addition, whether some adverse reactions, such as thromboembolic events, seizures and tinnitus, are related to the vaccine remains to be proven. Vaccines and hematologic diseases are summarized as: no live vaccines, inactivated vaccines are relatively safe, low vaccine efficiency in potentially treated patients, and the benefits of vaccination outweigh the harms, with no data for or against yet, and guidelines will continue to be adjusted based on data. Whether patients with non-Hodgkin’s lymphoma (inert/malignant) should receive the New Crown vaccine (version 5.0; last updated February 5, 2021) Vaccination with the New Crown vaccine is safe and appropriate for patients with aggressive lymphoma. No data are available on the safety and efficacy of the vaccine in immune-compromised patients. In general, it is recommended that patients with aggressive lymphoma should receive the New Crown vaccine, although patients may fail to articulate an effective immune response. For patients receiving a rituximab-containing regimen, decisions regarding the timing of vaccination must be individualized based on the prevalence of neostriatal in the community, the patient’s ability to self-isolate and the ability of their family and caregivers to self-isolate, the expected duration of treatment, and the availability of the vaccine. Rituximab blunts or completely eliminates the humoral response to the vaccine and is ineffective for at least 3-4 months of discontinuation. However, T-cell responses may provide a degree of protection or reduce the severity of infection, thus justifying vaccination during or after completion of therapy. Acute lymphoblastic leukemia (version 2.1; last updated January 22, 2021) is considered safe and appropriate as long as it is not a live, attenuated viral vaccine. For neo-crown, no data are publicly available regarding vaccine safety and efficacy in immune-compromised patients. It is recommended that all patients with receive neo-crown vaccine (not live vaccine), although an effective immune response may not have been generated at the time of chemotherapy, pending trial results. Pediatric acute lymphoblastic leukemia (version 3.0; last updated January 29, 2021) is considered safe and appropriate as long as it is not a live, attenuated vaccine. Data on vaccine safety and efficacy in immune-compromised patients have not been published. Vaccination is recommended in older children. However, patients with hypersensitivity to pemantel or asparaginase should not be vaccinated. Pfizer’s mRNA vaccine should not be administered to older patients until completion of the treatment phase that includes asparaginase and other booster treatment phases. It is best not to vaccinate with Neocrown vaccine until asparaginase therapy has been completed. Acute myeloid leukemia (version 1.5; last updated January 22, 2021) Vaccination is allowed as long as it is not a live attenuated virus vaccine. For neo-crown, there are no published data on the safety and efficacy of the vaccine in immune-compromised patients. Although an effective immune response may not be generated with chemotherapy, trial results are awaited Chronic lymphocytic leukemia (version 4.1; last updated February 2, 2021) Vaccine safety should be evaluated on a case-by-case basis for each patient based on reported side effects and patient comorbidities, but in general, we recommend its use in patients.BTKis (ibrutinib, etc.) may transplant neo-coronaviruses, but also suppress patient immunity. However, they can also suppress patient immunity. Patients with chronic myeloid leukemia (version 2.0; last updated January 4, 2021) are considered suitable for vaccination with the neostriatal vaccine. Although rare exceptions may exist, most patients, whether in early treatment, sustained remission, deep remission, or seeking a “treatment-free remission” non-therapeutic approach, may be appropriate and should be vaccinated when possible. Usually, for patients with CML, there is neither an undue risk of side effects nor a concern about effectiveness. Hodgkin’s lymphoma (version 5.0; last updated February 5, 2021) Vaccination with the New Crown vaccine is generally safe and appropriate for patients with Hodgkin’s lymphoma. No data are available on the safety and efficacy of the vaccine in immune-compromised patients. In general, we recommend that patients with Hodgkin’s lymphoma should be vaccinated with the New Crown vaccine, although a robust immune response may not be generated. Decisions regarding the timing of vaccination must be individualized based on the prevalence of neointima in the community, the patient’s ability to self-isolate and the ability of their family and caregivers to self-isolate, the expected duration of treatment, and the availability of the vaccine. Myelodysplastic syndromes (version 4.1; last updated January 22, 2021) Vaccination is safe and appropriate. Data on vaccine safety and efficacy in immune-compromised patients are not yet publicly available. As a general statement, we support patients with MDS receiving the New Crown vaccine (non-live vaccine), although they may not have developed an effective immune response, pending trial results. Chronic myeloproliferative neoplasms (version 6.0; last updated January 25, 2021) The vaccine may not pose an additional risk to patients, but interferons, for example, can reduce vaccine efficacy. Patients with systemic mastocytosis/MPN overlap syndrome, etc. should not be vaccinated. Aplastic anemia (version 2.0; last updated November 30, 2020) Cases have been reported of reoccurrence after vaccination, as well as recurrence of reoccurrence after vaccination. However, in the context of a neointimal pandemic, the benefits outweigh the harms, especially in patients at risk for other serious neointimal diseases (eg, age, obesity, other comorbidities associated with increased risk). Patients within 6 months of initiation of ATG/cyclosporine are unlikely to develop an immune response to the vaccine, and if immunization is necessary, passive antibody therapy or transfusion of plasma from an infected curee may be considered. Patients on cyclosporine maintenance therapy after ATG treatment may respond to the new crown vaccine, but definitely produce low antibodies; no study data are available. Patients are unlikely to respond to the vaccine within 6 months after allogeneic transplantation or when GVHD occurs. Post-transplant patients should follow standard post-transplant guidelines for vaccination. Thalassemia (version 2.0; latest review September 22, 2020) There are no contraindications to vaccination for thalassemia. Thalassemia would theoretically have a high rate of infection, but fewer than expected develop a new crown, probably due to earlier and more vigilant self-isolation. Splenectomy does not increase the risk of viral infection or serious viral disease, but specific data for neo-crown are not available. Currently, there are no data to suggest that neostriatal virus can be transmitted by blood donation (but there is no evidence if it can), and transfusion programs should not be delayed. There are no data on iron removal and susceptibility to neo-crown or severity of infection. If a patient is exposed but asymptomatic, there is no reason to interrupt iron removal. If the patient is symptomatic, especially with moderate to severe disease, interruption of iron removal is recommended with ongoing communication between the treating physician and the hematologist. What is the recommendation for stem cell transplantation or gene therapy for thalassemia during a new crown pandemic? Most allogeneic stem cell transplants and gene therapies were postponed at the beginning of the neo-coronary pandemic due to the high risk of infection in the hospital and the risk of reperfusion crisis. In areas where hospitalizations for neo-crown are declining, patients and their physicians can begin to discuss procedures as planned, especially for patients who are ready for gene therapy or an allogeneic donor. There is no evidence that neo-crown can be transmitted through hematopoietic stem cell grafts.